Should I Have Surgery To Cure Ulcerative Colitis?
Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half
This surgery has become standard because it cures ulcerative colitis and allows nearly normal bowel movements. 1 Proctocolectomy and ileostomy. The large intestine, the rectum, and sometimes the anus are removed (proctocolectomy). The surgeon sews the anus closed and makes a small opening (stoma) in the skin of the lower abdomen. The ileum attaches to the opening in the abdomen. Stool empties into an ostomy bag that attaches to the stoma. Ileoanal anastomosis is the surgery that is most often done. This surgery is successful in 95% of people who have it. 1 Most young people with ulcerative colitis have ileoanal surgery. Proctocolectomy is done for people with ulcerative colitis who cannot be under anesthesia for long periods of time because of illness or age. Continue taking medicines to see if your symptoms improve. Have surgery to remove your colon, curing ulcerative colitis. discover here http://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/should-i-have-surgery-to-cure-ulcerative-colitis
Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery, says William Sandborn, M.D. , a Mayo Clinic gastroenterologist and lead author of the study. We found that treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo. In this multi-center, international study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent (630 of 728) had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13 percent (98 of 728) of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at 0, 2 and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41 percent in outpatients with moderately-to-severe active ulcerative colitis. The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (p=0.02). Compared with placebo, fewer ulcerative colitis-related hospitalizations and surgeries/procedures occurred with infliximab therapy. One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon, says Dr. Sandborn. Our research hopes to provide other treatment solutions for patients beyond surgery. Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explains Dr. Sandborn. bonuses http://www.newswise.com/articles/ulcerative-colitis-treatment-reduces-need-for-surgery-by-almost-half
Ulcerative Colitis Treatment & Management
If you do not want us to use the random number for purposes similar to the purposes for which we use cookies, as described in this Privacy Policy, please do not use Medscape Mobile. Also, if you do become a registered user of Medscape Mobile, we will use your registration information as described in this Privacy Policy to provide the Services to you through Medscape Mobile. We do not obtain any information about your mobile device (through the random number, your registration information or otherwise) other than its brand, make and model and the type of operating software that it uses. Children's Privacy We are committed to protecting the privacy of children. The Professional Sites and Services are designed and intended for use by adults, and are not intended for, nor designed to be used by children under the age of 18. We do not collect personally identifiable information from any person we know is under the age of 18. Uses and Disclosures We Make of Information In this section of our Privacy Policy, we identify the ways we may use information about you that we have collected. In general, the personally identifiable information that you provide in connection with the Services will be used to provide the services you have requested or authorized. Aggregate Data We create aggregate data about users of our Services for product development and improvement activities. We also use it for market analysis. We may provide information about users of our Services in aggregate form to third parties. my response http://emedicine.medscape.com/article/183084-treatment
This surgery has become standard because it cures ulcerative colitis and allows nearly normal bowel movements. 1 Proctocolectomy and ileostomy. The large intestine, the rectum, and sometimes the anus are removed (proctocolectomy). The surgeon sews the anus closed and makes a small opening (stoma) in the skin of the lower abdomen. The ileum attaches to the opening in the abdomen. Stool empties into an ostomy bag that attaches to the stoma. Ileoanal anastomosis is the surgery that is most often done. This surgery is successful in 95% of people who have it. 1 Most young people with ulcerative colitis have ileoanal surgery. Proctocolectomy is done for people with ulcerative colitis who cannot be under anesthesia for long periods of time because of illness or age. Continue taking medicines to see if your symptoms improve. Have surgery to remove your colon, curing ulcerative colitis. discover here http://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/should-i-have-surgery-to-cure-ulcerative-colitis
Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery, says William Sandborn, M.D. , a Mayo Clinic gastroenterologist and lead author of the study. We found that treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo. In this multi-center, international study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent (630 of 728) had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13 percent (98 of 728) of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at 0, 2 and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41 percent in outpatients with moderately-to-severe active ulcerative colitis. The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (p=0.02). Compared with placebo, fewer ulcerative colitis-related hospitalizations and surgeries/procedures occurred with infliximab therapy. One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon, says Dr. Sandborn. Our research hopes to provide other treatment solutions for patients beyond surgery. Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explains Dr. Sandborn. bonuses http://www.newswise.com/articles/ulcerative-colitis-treatment-reduces-need-for-surgery-by-almost-half
Ulcerative Colitis Treatment & Management
If you do not want us to use the random number for purposes similar to the purposes for which we use cookies, as described in this Privacy Policy, please do not use Medscape Mobile. Also, if you do become a registered user of Medscape Mobile, we will use your registration information as described in this Privacy Policy to provide the Services to you through Medscape Mobile. We do not obtain any information about your mobile device (through the random number, your registration information or otherwise) other than its brand, make and model and the type of operating software that it uses. Children's Privacy We are committed to protecting the privacy of children. The Professional Sites and Services are designed and intended for use by adults, and are not intended for, nor designed to be used by children under the age of 18. We do not collect personally identifiable information from any person we know is under the age of 18. Uses and Disclosures We Make of Information In this section of our Privacy Policy, we identify the ways we may use information about you that we have collected. In general, the personally identifiable information that you provide in connection with the Services will be used to provide the services you have requested or authorized. Aggregate Data We create aggregate data about users of our Services for product development and improvement activities. We also use it for market analysis. We may provide information about users of our Services in aggregate form to third parties. my response http://emedicine.medscape.com/article/183084-treatment
Replies